Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethiqa XR is a veterinary **extended-release buprenorphine injectable suspension** developed by Fidelis Animal Health for control of post-procedural pain in laboratory and captive animal species including rodents, ferrets, rabbits, and non-human primates. The active ingredient is buprenorphine hydrochloride, a small-molecule opioid analgesic formulated using Fidelis Animal Health's long-acting lipid-based delivery technology to provide sustained analgesia for up to 72 hours after a **single subcutaneous injection**. Pharmacologically, buprenorphine acts primarily as a **partial agonist at the mu-opioid receptor**, producing analgesia through modulation of opioid signaling. Ethiqa XR is an FDA-indexed veterinary product and a Schedule III controlled substance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ethiqa XR.